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Abstract The coexistence of different types of trigeminal
autonomic cephalalgias is a rare phenomenon. The two
different types of headache may occur either at two dif-
ferent periods or simultaneously at the same time. We
report a 22-year-old male who had cluster headache (CH)
and chronic paroxysmal hemicrania (CPH) since the onset
of symptoms. Both types of headache responded to
indomethacin. Review of the literature suggests that
simultaneous occurrence of CH and CPH in a patient may
be both over and under reported.
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Introduction
The coexistence of different primary headache disorders is
not rare. However, there are only a few case reports of the
coexistence of two different varieties of trigeminal auto-
nomic cephalalgias (TACs) in the same patient. The two
different types of headache may occur either at two dif-
ferent time periods or simultaneously at the same time
[1–5]. Here we report a patient with ipsilateral attacks of
cluster headache (CH) and chronic paroxysmal hemicrania
(CPH) at the same time. We also review the literature on
coexisting CH and paroxysmal hemicrania (PH).
Case
A 22-year old male presented with a 13-month history of
recurrent daily headache. The pain, strictly on the left side,
was centered on the left orbit radiating to frontal and infra
orbital areas. The patient described the headache as very
severe, sharp, and tearing type. The patient noticed two
types of headache, one with a shorter and another with a
longer duration. The usual duration of headache was
5–20 min for shorter duration type, and 2–3 h for longer
duration type. However, overall the duration of attacks was
variable, few minutes to few hours (up to 5 h). The quality
and severity of the pain was similar in almost all the epi-
sodes. Most of the attacks were associated with ipsilateral
lacrimation, conjunctival injection, ptosis and rhinorrhea.
There were occasional nausea, photophobia, and phono-
phobia. The patient denied the presence of any type of
symptoms (including mild background headache) between
two episodes of headache. During most of the attacks the
patient cried or paced. There were occasional nocturnal
attacks. No precipitating or aggravating factors were noted.
The frequency of attacks was highly variable. He had a
history of 10–25 short-lasting attacks in a day. He used to
have four to ten attacks of longer duration in a week. The
pain used to start abruptly. He could not predict (in early
part of the attack) which attacks were going to last longer.
The patient received a lot of drugs before reporting to
us. He took paracetamol, naproxen, oral sumatriptan and
rizatriptan (as abortive treatment) on many occasions
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during the attack. There was history of improvement at
several times within few minutes to 60 min after the
administration of triptans. However, the patient was not
sure about the efficacy of triptans as he had history of
frequent attacks of shorter duration. Oxygen inhalation
during an attack had never been tried. Prior prophylactic
treatment with amitriptyline, flunarizine, paracetamol,
naproxen, sodium valproate, and propranolol produced
minimal or no effect.
The patient had no prior history of headache. Family
history for headache was negative. He was nonalcoholic
and a non-smoker. General and neurological examinations
between two attacks were normal. Routine haematological
and biochemical screening was normal. Magnetic reso-
nance imaging of brain, orbit, pituitary and cervical spine
revealed no abnormality. Magnetic resonance angiography
was reported as normal.
We started indomethacin at a dose of 25 mg tds. With
this dose, he felt marked improvement in the frequency of
the ‘shorter duration’ type of headache. In the next
10 days, the frequency of attacks was about less than one
attack in a day. However, the frequency and intensity of the
‘longer duration’ type of headache remained unchanged.
The dosage of indomethacin was gradually increased. At
the dose of 50 mg tds, the shorter duration attacks subsided
completely and frequency of longer duration attacks
decreased to two in the next week. The dosage of indo-
methacin was further increased. The longer duration
attacks subsided completely at the dosage of 100 mg tds
(with famotidine for gastric protection). In the next
5 months of follow up (with indomethacin), he did not
have any attack of headache.
Discussion
The TACs, a group of primary headache disorder, include
CH, PH, and short-lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing (SUNCT).
These differ in attack duration, frequency, and the response
to therapy. The duration of an attack of different TACs
according to the International Headache Society (IHS)
criteria are 5–240 s (SUNCT), 2–30 min (PH), 15–180 min
(CH). The frequency of different TACs are: SUNCT
(3–200 per day), PH ([5 attacks per day for more than half
the time), and CH (1 per alternate day to 8 per day).
Response to indomethacin is an essential criterion for the
diagnosis of PH [6].
Our patient distinctly recognized two types of headache,
short-lasting (5–20 min) and long-lasting attacks (2–5 h).
Many authors have suggested a trial of indomethacin at the
start of treatment to detect the indomethacin-sensitive
group in all patients diagnosed with TACs. Both the types
of attacks showed response to indomethacin. We noted
dose-response relation with indomethacin. The short
attacks were eliminated at the dose of 50 mg tds. However,
100 mg tds dose was required for cessation of the longer
attacks. As the patient showed marked response with
indomethacin within a few days, we did not give the trial
oxygen inhalation.
The whole spectrum of frequency and duration of the
disease was not fitting in any one primary headache dis-
order. The foot note of IHS diagnostic criteria quote
‘During part (but less than half) of the time-course of CH,
attacks may be less severe and/or of shorter or longer
duration’. However, the frequency of 10–25 attacks in a
day (almost daily) was against the diagnosis of CH. In the
same way, duration of an attack up to 5 h was against the
diagnosis of PH. The absence of background headache
ruled out the possibility of hemicrania continua (HC).
The shorter attacks completely fulfilled the IHS criteria
for PH. The mean length of an attack of CPH is 17–21 min.
The maximum reported duration of an attack is usually
3–4 h [7, 8]. However, Boes et al. [7] in a retrospective
study on 74 patients of CPH found one patient with few
attacks of 6 h duration. Cittadini et al. [8] in a prospective
study on 31 patients of PH reported a patient who had an
attack of 48 h. Hence, one possible diagnosis in our case
could be CPH, similar to the cases reported by Boes et al.
and Cittadini et al. However, our case was different in that
long-lasting attacks (up to 5 h) were more frequent. Hence,
another possible diagnosis in our case would be simulta-
neous occurrence of probable chronic cluster headache
(CCH) and probable CPH.
To date, we found only five cases in the literature where
authors claimed the presence of CH and PH in the same
patient (simultaneously or at two different periods of life)
(Table 1). The first case report of CPH and CH in a same
patient was described by Jotkowitz [1] in a 41-year-old-
male in whom the pattern of headache (frequency and
duration) changed after 4 years. Initially, he had 1–3
headaches per day, each lasting 45–60 min. Indomethacin
was not tried during these periods. Later on, after 4 years,
frequency increased up to 8 per day and duration shortened
to 20–30 min. The patient showed marked response in the
frequency and severity of the headaches with indomethacin
(150 mg/day). The author concluded that initial attack was
typical of episodic CH and later on, it changed to CPH.
Pearce et al. [2] reported a female patient who had
history of migraine (16–20 years of age), episodic cluster
headache (ECH) (48–47 years), and PH (a single bout at
58 years) at different periods in life. The patient’s single
episode of PH showed response to indomethacin after
22 days of therapy. There was no recurrence of PH like
headache in about 7 months’ follow up even after
withdrawal of the drug.
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Tehindrazanarivelo et al. [3] described two cases of
ipsilateral CH and CPH. Both patients, who had been
suffering from CH for many years ([5 years), developed
simultaneous attacks of PH with the attacks of CH. Both
patients received indomethacin and verapamil at the same
time, and it was concluded that indomethacin was effective
for short-lasting attacks and verapamil for long-lasting
attacks. However, an attempt to control both the types of
attacks with a single drug (either verapamil or indometh-
acin) with maximal possible dose was not done. In the first
case, short-lasting attacks of PH responded to indometha-
cin (150 mg/day). Verapamil was added for longer attacks
and patient responded to 360 mg daily. Indomethacin was
tapered off after 6 weeks. There was no recurrence in the
next 14 months. In the second patient, verapamil was
started as initial drug and long-lasting attacks of CH sub-
sided at the dose of 240 mg daily. Indomethacin (200 mg
daily) was added for short-lasting attacks. There was no
recurrence of attacks even after tapering off and stopping
of indomethacin in about next 12 months.
Another case of simultaneous occurrence of CH and PH
was described by Centonze [4] in a 42-year-old male. The
patient with the history of ECH for about 6 years devel-
oped PH-like attacks (short duration and higher frequency)
in a fresh episode of CH. The patient was already on
verapamil (360 mg daily) for ECH. Indomethacin was
added, and patient noted complete improvement on shorter
attacks and partial improvement of longer attacks at the
dose of 225 mg daily. After 3 weeks, indomethacin was
successfully discontinued. In about 9 months of follow up,
there was no recurrence of shorter attacks.
Gobel et al. [5] reported successive occurrence of tri-
geminal neuralgia, SUNCT-syndrome, CPH and CH in one
active headache period in a 47–year-old male. However, it
is difficult to derive any conclusion from this case report
(published in abstract form) as the details of CPH and CH
are lacking.
The episodic form of PH is less frequent than chronic
form of PH (in contrast to CH). There are just a few case
reports of episodic form of PH in the literature [9]. Hence,
co-occurrence of CH with CPH would be perhaps possible
rather than the co-occurrence of CH with EPH, which is
itself very rare. However, all the above-reported cases of
PH (with CH) are episodic in nature. At least two episodes,
separated by at least 1 month of pain remission, are
required to satisfy the IHS diagnostic criteria for episodic
paroxysmal hemicrania (EPH) [6]. However, no patient had
two or more episodes of PH-like attacks (frequency and
duration) in the history. Moreover, no patient had a trial of
an increased dose of previously effective drugs.
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Com. relief by Indo.
in PH
Only 1 episode of PH (no
recurrence after
withdrawal of indo)a
Response by indo. in
22 days
Tehindrazanarivelo et al. [3]




Past history of CH
Recent attacks include
both PH and CH
Verapamil for CH
Indo. for PH
Only 1 episode of PH (no
recurrence after
withdrawal of indo)a




Past history of CH
Recent attacks include
both PH and CH
Verapamil for CH
Indo. for PH
Only 1 episode of PH (no
recurrence after
withdrawal of indo)a




Past history of CH
Recent attacks include
both PH and CH
Verapamil for CH
Indo. for PH
Only 1 episode of PH (no
recurrence after
withdrawal of indo)a
Gobel et al.b [5] 47/M b b b b b
a At least two attacks separated by pain-free remission periods of C1 month are required for IHS criteria of EPH
b Details not available
com complete, d duration, f frequency, Indo Indomethacin, mts minutes, Y years
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In Pearce et al. case report the response to indomethacin
was not immediate. Response occurred 22 days after
administration of indomethacin therapy. All reported case
series of EPH showed response within 24 h after the
administration of indomethacin. This further created the
doubt about the diagnosis of PH in this patient.
There is considerable overlap in the diagnostic criteria
of CH and PH in the IHS classification. The headache
duration of 15–30 min and headache frequency of 5–8 in a
day is common for both CH and PH [6]. Even after the
change of duration and frequency of headache, Jotkowitz’s
case satisfies the IHS criteria for CH.
The overlap between CH and PH becomes more evident
when one reviews the clinical profiles of both these pri-
mary headache disorders. In the patients of CH, the
duration of an attack may be as low as 2 min and the
frequency may be as high as 30 in a day [10, 11]. The
frequency of ECH might increase and of CCH may
decrease over the years [12]. There is considerable overlap
between CH and PH even in treatment modalities.
Therefore, the aforementioned cases may not be true
representations of CH and PH in the same patient. The
possibility of fluctuation (frequency and duration) of CH
attacks itself (or? atypical form) cannot be ruled out.
Leon et al. [13] reported a 55-year-old woman with
recurrent bouts (of 2 months) of headache since her ado-
lescence. In adolescent and adulthood periods, individual
attacks were of 20 min. The frequency of attacks was 4–6
times in a day. The attacks were controlled with 150 mg of
indomethacin. There was a change in headache periodicity
and frequency during 47–55 years of age. There was no
remission period during these 8 years and headache fre-
quency increased to 15 attacks in a day. The patient needed
400–500 mg of indomethacin to control this changed pat-
tern of headache. After 8 years of continuous headache
attacks, the pattern of headache reverted to the previous
pattern (requiring 150 mg indomethacin daily). The
authors reported these two types of attacks as EPH and
CPH. However, Lipton et al. (after reviewing this case)
suggested that her early attack was ECH that evolved into
CPH [14]. This case fulfilled the IHS criteria of both HC
and CPH (in two different period of life), and it may be the
true representation of CH and PH in the same patient.
Blau et al. [15] reported recurrent bouts (11–13 weeks)
of headache since the age of 16 in a 40-year-old female. In
each bout, during the first and third months she had two to
three attacks in a day. In the second month, the frequency
of headache used to increase up to one in an hour. Indi-
vidual attacks persisted for 10–20 min. The patient showed
complete response to indomethacin (150 mg daily) and
prednisolone separately on two different occasions. The
author’s diagnosis was EPH. However, she was diagnosed
as a case of CH in the past. This case poses a diagnostic
problem, as the frequency of headache attacks does not fit
into any IHS classification of primary headache disorders.
The headache attacks in the first and third months fulfilled
the criteria of CH. However, in the second month of a bout
it was EPH. Therefore, this patient might have diagnosis of
either EPH with fluctuating frequency, CH with fluctuating
frequency or a combination of both EPH and ECH.
Our case was probably an example of co existence of
CPH and CCH. It is probably the first case where features
of both CH and PH were present since the onset. However,
we cannot rule out the possibility of either PH or CH alone
(with marked variation in the frequency and duration of
attacks). The presence of nausea, photophobia, phonopho-
bia, response of oral triptans on few attacks may suggest
overlap of migraine in the patient. However, these features
are not uncommon even in pure form of PH and CH [7, 8,
10]. Another unique point in this patient was response to
both the types of headache attacks by a single-drug therapy
(indomethacin). Response to two different types of head-
ache by a single agent has been reported in only one patient
in the literature. Rozen [16] reported a patient with
simultaneous occurrence of both HC and CH in the same
individual. Both types of headache syndromes responded to
verapamil.
Response to indomethacin is an essential criterion for
the diagnosis of PH. Indomethacin is considered as a drug
ineffective for the patients of CH. Although response to
indomethacin is not against the IHS criteria for CH, phy-
sicians hesitate in making the diagnosis of CH if a patient
shows response to indomethacin, even in those people who
clearly fulfil the IHS criteria for CH. There are many
reports in the literature where cases of CH were wrongly
diagnosed as PH because of the presence of positive
response to indomethacin [9, 13, 17]. Indomethacin has
never been evaluated systematically for CH prophylaxis.
There are many case reports in the literature where indo-
methacin was effective in the patients of CH [18, 19].
Trigeminal autonomic reflex (TAR) (consists of a
brainstem connection between trigeminal nerve and facial
parasympathetic outflow) is considered essential for the
manifestations of the trigeminal autonomic pain syn-
dromes. Activation of trigeminal autonomic reflex is
responsible for the acute attacks of TACs. The triggering
factor for the activation of this reflex is probably situated in
the hypothalamus or a closely related structure [20].
However, the duration and frequency of headache attacks
depend on what side (or type of neuron) of the hypothal-
amus is activated [20]. In CH hypothalamic activation
occurs ipsilateral to the side of the headache while in PH
hypothalamic activation occurs contralateral to the side of
headache [20]. Activation of two different sites may be a
possible explanation for variability in the duration of
attacks in our patient.
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Our review of the literature suggests that co-occurrence
of CH and PH may be both over and under diagnosed. This
is because of the overlap in the frequency and pattern of
both the diseases. Response to indomethacin is another
critical point regarding this issue. One should be very
careful in making the diagnosis PH just because of the
presence of response to indomethacin. Our case further
strengthens the view that marked overlaps exist between
CH and PH, and these two may not be two discrete entities
(as suggested by many authors) [19]. Moreover, the
responses to one single agent for two different headache
syndromes in our patient and in Rozen’s case report sug-
gests that the dose of previously effective drug should be
increased (rather than to add new drug) for the change in
the pattern of headache and for co existence of two dif-
ferent types of headache syndrome at the same time.
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